Selection of valve and procedural anticoagulant type may impact bleeding and vascular complications in transfemoral transcatheter aortic valve replacement (TAVR). We sought to compare outcomes by valve [balloon expandable (BE) or non-BE] and anticoagulant [bivalirudin vs. unfractionated heparin (UFH)] type from the BRAVO-3 trial.
Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement. results from the BRAVO 3 randomized trial / Linke, A., Chandrasekhar, J., Sartori, S., Lefevre, T., van Belle, E., Schaefer, U., Tchetche, D., Sardella, G., Webb, J., Colombo, A., Windecker, S., Vogel, B., Farhan, S., Sorrentino, S., Sharma, M., Snyder, C., Asgar, A., Dumonteil, N., Tamburino, C., Hink, U., et al.. - In: CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS. - ISSN 1522-1946. - ELETTRONICO. - 90:5(2017), pp. 1016-1026. [10.1002/ccd.27154]
Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement. results from the BRAVO 3 randomized trial
SARDELLA, Gennaro;Violini, Roberto;
2017
Abstract
Selection of valve and procedural anticoagulant type may impact bleeding and vascular complications in transfemoral transcatheter aortic valve replacement (TAVR). We sought to compare outcomes by valve [balloon expandable (BE) or non-BE] and anticoagulant [bivalirudin vs. unfractionated heparin (UFH)] type from the BRAVO-3 trial.| File | Dimensione | Formato | |
|---|---|---|---|
|
Linke_Effect-Of-Valve_2017.pdf
solo gestori archivio
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
1.02 MB
Formato
Adobe PDF
|
1.02 MB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
